Jia-Ren Lin

headshot_jiarenlin.jpg

I received my Bachelor’s degree from the National Taiwan University (Taipei, Taiwan) in 2000. Later I went on to receive my PhD in 2012 from Stanford University (Stanford, California, USA). During my Ph.D. research, I has received the DOD breast cancer research program traineeship award in 2009.  From my PhD study, I have published several high-impact papers about DNA damage response and cell cycle regulation on Molecular Cell, a prestigious journal in the cell & molecular biology field.  After graduation, I worked as a Postdoc in Dr. Cimprich’s lab at Stanford University.  In 2013, I moved to Harvard Medical School and joined the Laboratory of Systems Pharmacology as a postdoc.

I am currently in the Laboratory of Systems Pharmacology for my postdoctoral research.  My work is to cultivate contemporary computational and experimental approaches for understanding drug-gene interactions in cancers, with specific focus on developing new imaging methods either for high-content/live-cell imaging in researching settings or multiplexed methods for clinical samples. My goal is to elucidate how genetic changes lead to heterogeneous responses of singling network, and to use this information for developing more effective therapeutic approaches.

 

Recent Publications

2024

Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J-R, Muhlich J, Mittendorf E, Santagata S, Guerriero J, et al. Quality control for single cell analysis of high-plex tissue profiles using CyLinter. bioRxiv. 2024.
Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J-R, Muhlich J, Mittendorf E, Santagata S, Guerriero J, et al. Quality control for single cell analysis of high-plex tissue profiles using CyLinter. bioRxiv. 2024.
Guerriero J, Lin J-R, Pastorello R, Du Z, Chen Y-A, Townsend M, Shimada K, Hughes M, Ren S, Tayob N, et al. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024;10(1):2.
Guerriero J, Lin J-R, Pastorello R, Du Z, Chen Y-A, Townsend M, Shimada K, Hughes M, Ren S, Tayob N, et al. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024;10(1):2.
Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates. Clinical Cancer Research. 2024;30(7):1281–1292.
Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates. Clinical Cancer Research. 2024;30(7):1281–1292.
Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Jadeja S, Murphy G, Nirmal A, Lian C, Sorger P, et al. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study. The Journal of investigative dermatology. 2024:S0022–202X.
Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Jadeja S, Murphy G, Nirmal A, Lian C, Sorger P, et al. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study. The Journal of investigative dermatology. 2024:S0022–202X.
Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J-R, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer. Journal of Clinical Oncology. 2024;42(11):1311–1321.
Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J-R, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer. Journal of Clinical Oncology. 2024;42(11):1311–1321.

2023

Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Murphy G, Nirmal A, Lian C, Sorger P, LeBoeuf N. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence. bioRxiv. 2023:2023–04.
Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Murphy G, Nirmal A, Lian C, Sorger P, LeBoeuf N. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence. bioRxiv. 2023:2023–04.